Latest news with #Meitheal
Agriland
7 days ago
- Business
- Agriland
Galway Wool Co Op Partners with Avoca to Expand Range
Galway Wool Co-Op's fifth annual Meitheal, which will take place at Athenry livestock mart next weekend, coincides with the announcement of the wool co-op's business partnership with Avoca Woollen Mills. Blátnaid Gallagher of Galway Wool Co-op said: "We are thrilled to partner with Avoca, a brand that shares our passion for quality and Irish tradition. "This collaboration gives a national platform to our wool growers and demonstrates the strength of a community-based wool harvest," The launch of the partnership will take place at the mart on on Saturday, July 19 at 9:00am. Following a successful pilot project completed last year, Galway Wool Co-Op discovered that not only micron count, but crucially the processing method, plays a central role in how Irish wool is transformed into yarn. "The findings revealed that with more careful handling, the wool can achieve significantly greater softness, a smoother finish, and improved handle, making it far more suitable for wearables, tweed, blankets, and fine textiles," Gallagher said. "Over the past four years, the wool harvest has been sponsored by Donegal Yarns, which has spun the wool into durable yarns, best suited for carpets and floor rugs. Source: David Ruffles "Now, with enhanced worsted spinning techniques and greater attention to detail, our rare breed native Irish yarn can be used in a much wider range of applications." According to Gallagher, this opens exciting new possibilities for clothing, accessories, tweed and interior textiles, making the 2025 harvest "one of the most promising and versatile to date". "Central to this new partnership is Avoca's belief that the wool growers of this rare heritage Irish breed deserve to be rewarded for their dedication. "The Galway Wool Co-Op said that a trade price of €2.50 per kilo will be achieved for the fifth year running,`' she said. This consistent price honours the hard work and care of growers who are helping to preserve this rare breed, Gallagher contended. "These farmers, drawing wool from the four corners of Ireland, take pride in presenting their fleece in the pristine rolled traditional manner, upholding a vital part of our cultural and agricultural heritage," she said. "The Galway is officially recognised as Ireland's native breed, thanks to over 103 years of commitment from a small group of dedicated farmers. "They began maintaining the breed's flock book at a time when many of Ireland's weaving and mills were producing world renowned Aran sweaters from this unique Báinín yarn. "That was before they shifted towards imported merino wool from as far afield as China and South Africa," the Galway Wool Co-Op spokesperson added. Gallagher explained that, against the odds, these farmers - supported by the Department of Agriculture, Food and the Marine - have grown their breed society into one of the largest in the country. "While overall flock numbers remain modest, renewed interest in the Galway's distinctive Báinín wool and succulent lamb has given a welcome boost to efforts to ensure the survival and revival of this important part of Ireland's agricultural heritage," she said. The Meitheal - a traditional Irish gathering for communal work - celebrates the revival of native Irish wool from the Galway sheep breed, and rural collaboration. "This year, with Avoca Woollen Mills on board, the event represents a powerful step towards sustainable Irish-made from locally sourced wool into textiles and increased market opportunities for wool growers of this treasured breed across Ireland," Gallagher said. The Meitheal will feature wool-handling demonstrations, a spinning workshop, and an artisan showcase of the many applications and iterations of native Irish yarn from the Galway breed.
Irish Independent
23-07-2025
- Business
- Irish Independent
Avoca to craft new range with rare Irish wool
All 4.5 tonnes of yarn from Galway Wool Co-Op's 2025 harvest will be sold exclusively to Avoca and woven into clothing and homewares for a 100pc native Irish wool collection, debuting as part of the brand's autumn-winter collection. Known for its colourful weaves and dedication to supporting Irish producers, for Avoca this partnership is an exclusive collaboration, also supporting a full farm-to-textile journey, championing homegrown materials and traditional Irish craftsmanship in a contemporary way. The announcement comes as Galway Wool Co-Op prepares for the 2025 Meitheal, where wool will be harvested from a rare-breed sheep before being transformed into yarn. The Galway Wool Co-Op was founded five years ago with a mission to restore and celebrate native Irish wool from a rare breed of sheep called 'The Galway'. The strong, white fleeces from this sheep are affectionately known in Irish as 'báinín'. Thanks to the tireless work of The Galway Breeders Sheep Association, with support from the Department of Agriculture, the Galway sheep has been saved from the brink of extinction. Since its establishment, the Co-Op has been committed to achieving a fair and consistent price for the wool that reflects the hard work put in by each grower. Avoca's support through the business partnership ensures that this fair pricing is maintained and offers increased commercial opportunities for wool growers across Ireland, preserving this wonderful native breed. Speaking ahead of the harvest, Avoca managing director Brian Handley said that they are so proud to work with The Galway Wool Co-Op as their first ever commercial partner. 'As one of Ireland's oldest mills, we are keenly aware of the challenges faced by local wool growers, so we are delighted to be able to support the Co-Op in a meaningful way while bringing this beautiful, sustainable product to our customers,' Mr Handley said.
Yahoo
29-05-2025
- Business
- Yahoo
Meitheal Pharmaceuticals Announces Launch of Generic Paclitaxel Formulation in the United States Through Exclusive Commercial Licensing Agreement
Meitheal, through parent company Hong Kong King-Friend, launches generic paclitaxel Protein-bound paclitaxel formulation is used to treat various types of cancer, including metastatic breast cancer and metastatic adenocarcinoma of the pancreas More than 168,000 people live with metastatic breast cancer in the U.S., with only one-third of patients surviving 5 years after diagnosis1 Bringing paclitaxel to market underscores Meitheal's commitment to meeting patients' needs through a sustainable, affordable supply of critical medicines CHICAGO, May 29, 2025--(BUSINESS WIRE)--Meitheal Pharmaceuticals, Inc. ("Meitheal"), a fully integrated biopharmaceutical company based in Chicago and focused on the development and commercialization of generic injectables, fertility, biologic, and branded products, today announced it has launched, through an exclusive license and supply agreement with its parent company, Hong Kong King-Friend Industry Co., Ltd. ("HKF"), paclitaxel protein-bound particles for injectable suspension (albumin-bound), a generic form of Abraxane®2, in the U.S. The 100mg/vial single-dose presentation of protein-bound paclitaxel for injectable suspension is indicated for the treatment of metastatic breast cancer, metastatic adenocarcinoma of the pancreas, and locally advanced or metastatic non-small cell lung cancer. "Many patients living with difficult-to-treat cancers are faced with the unfortunate reality that the complex, life-saving treatments they need are too expensive or unavailable. At Meitheal, we're committed to closing this gap – we believe that today's launch is critical to ensuring that cancer patients get the medicines they need," said Tom Shea, Chief Executive Officer of Meitheal. "We're excited to bring this to market in the U.S. and provide patients and providers with a reliable supply of an effective cancer care treatment." The launch of paclitaxel increases Meitheal's portfolio of on-market generic injectables to 68 products, and builds on Meitheal's successful 12 product launches in 2024. In addition to paclitaxel, Meitheal is planning to launch 20 new products this year across its core therapeutic areas as it continues to identify gaps in the marketplace and evaluate opportunities to address the needs of both patients and providers. ABOUT PACLITAXELPaclitaxel protein-bound particles for injectable suspension (albumin-bound) is a type of chemotherapy, interfering with microtubules and causing cancerous cells to die. Paclitaxel is largely used for the treatment of metastatic breast cancer, and additional types of cancer. IMPORTANT SAFETY INFORMATIONINDICATIONSPaclitaxel protein-bound particles for injectable suspension (albumin-bound) is a microtubule inhibitor indicated for the treatment of: Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. SELECT IMPORTANT SAFETY INFORMATION WARNING: SEVERE MYELOSUPPRESSIONSee full prescribing information for complete boxed warning. Do not administer paclitaxel protein-bound particles for injectable suspension (albumin-bound) therapy to patients with baseline neutrophil counts of less than 1,500 cells/ for neutropenia, which may be severe and result in infection or frequent complete blood cell counts on all patients receiving paclitaxel protein-bound particles for injectable suspension (albumin-bound).CONTRAINDICATIONSNeutrophil counts of < 1,500 cells/mm3; and severe hypersensitivity reactions to paclitaxel protein-bound particles for injectable suspension (albumin-bound). WARNINGS AND PRECAUTIONSSensory neuropathy occurs frequently and may require dose reduction or treatment interruption. Sepsis occurred in patients with or without neutropenia who received paclitaxel protein-bound particles for injectable suspension (albumin-bound) in combination with gemcitabine; interrupt paclitaxel protein-bound particles for injectable suspension (albumin-bound) and gemcitabine until sepsis resolves, and if neutropenia, until neutrophils are at least 1,500 cells/mm3, then resume treatment at reduced dose levels. Pneumonitis occurred with the use of paclitaxel protein-bound particles for injectable suspension (albumin-bound) in combination with gemcitabine; permanently discontinue treatment with paclitaxel protein-bound particles for injectable suspension (albumin-bound) and gemcitabine. Severe hypersensitivity reactions with fatal outcome have been reported. Do not rechallenge with this drug. Exposure and toxicity of paclitaxel can be increased in patients with hepatic impairment, consider dose reduction and closely monitor patients with hepatic impairment. Paclitaxel protein-bound particles for injectable suspension (albumin-bound) contains albumin derived from human blood, which has a theoretical risk of viral transmission. Paclitaxel protein-bound particles for injectable suspension (albumin-bound) can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception. ADVERSE REACTIONSThe most common adverse reactions (≥ 20%) in metastatic breast cancer are alopecia, neutropenia, sensory neuropathy, abnormal ECG, fatigue/asthenia, myalgia/arthralgia, AST elevation, alkaline phosphatase elevation, anemia, nausea, infections, and diarrhea. DRUG INTERACTIONSUse caution when concomitantly administering paclitaxel protein-bound particles for injectable suspension (albumin-bound) with inhibitors or inducers of either CYP2C8 or CYP3A4. USE IN SPECIFIC POPULATIONS Lactation: Advise not to breastfeed. This is not the complete list of all the safety information for Paclitaxel protein-bound particles for injectable suspension (albumin-bound). Please click to see the full Prescribing Information for Paclitaxel protein-bound particles for injectable suspension (albumin-bound). ABOUT MEITHEAL PHARMACEUTICALS, in 2017 and based in Chicago, Meitheal is focused on the development and commercialization of generic injectable medications and, as of 2022, has expanded its focus to include fertility, biologic, and branded products. Meitheal currently markets over 60 U.S. FDA-approved products across numerous therapeutic areas including anti-infectives, oncolytics, intensive care, and fertility. As of April 2025, Meitheal, directly or through its partners, has 30 products in the research and development phase, 16 additional products planned for launch in 2025, and 23 products under review by the FDA. Meitheal's mission is to provide easy access to fairly priced products through robust manufacturing, consistent supply, and rapid response to our customers' needs. Ranked #2 in 2024 on Crain's Fast 50 in Chicago, and in the top 100 of Crain's Best Places to Work in Chicago from 2022 to 2024, Meitheal emulates the traditional Irish guiding principle we are named for—working together toward a common goal, for the greater good. Learn more about who we are and what we do at ABOUT HONG KONG KING-FRIEND INDUSTRIAL COMPANY (HKF)Hong Kong King-Friend Industrial Company is a wholly owned subsidiary of NKF, founded in 2010. ABOUT NANJING KING-FRIEND BIOPHARMACEUTICAL COMPANY (NKF)Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (NKF) is a China-based company principally engaged in the research and development, production and sales of Active Pharmaceutical Ingredients (API) and Finished Dosage Form (FDF). Established in 1986 as one of world leading manufacturers of heparin related APIs, NKF has grown into a fully integrated API and FDF manufacturer in multiple therapeutic areas including critical care and oncology. With three U.S. FDA approved manufacturing sites in China and more than 500 employees, including more than 100 dedicated research and development experts, NKF strives to meet patient needs globally with market presence in the U.S., China, EU and across the world. The Company is publicly listed on Shanghai Stock Exchange with a market capitalization over U.S. $3.0 billion. 1 Susan G. Komen Foundation. February 21, 2025. Metastatic Breast Cancer. 2 Abraxane® is a registered trademark of Celgene. View source version on Contacts MEDIA Meitheal Pharmaceuticals, Spilman, VP of Corporate Strategy773 899 5910info@
Yahoo
29-05-2025
- Business
- Yahoo
Meitheal Pharmaceuticals Announces Launch of Generic Paclitaxel Formulation in the United States Through Exclusive Commercial Licensing Agreement
Meitheal, through parent company Hong Kong King-Friend, launches generic paclitaxel Protein-bound paclitaxel formulation is used to treat various types of cancer, including metastatic breast cancer and metastatic adenocarcinoma of the pancreas More than 168,000 people live with metastatic breast cancer in the U.S., with only one-third of patients surviving 5 years after diagnosis1 Bringing paclitaxel to market underscores Meitheal's commitment to meeting patients' needs through a sustainable, affordable supply of critical medicines CHICAGO, May 29, 2025--(BUSINESS WIRE)--Meitheal Pharmaceuticals, Inc. ("Meitheal"), a fully integrated biopharmaceutical company based in Chicago and focused on the development and commercialization of generic injectables, fertility, biologic, and branded products, today announced it has launched, through an exclusive license and supply agreement with its parent company, Hong Kong King-Friend Industry Co., Ltd. ("HKF"), paclitaxel protein-bound particles for injectable suspension (albumin-bound), a generic form of Abraxane®2, in the U.S. The 100mg/vial single-dose presentation of protein-bound paclitaxel for injectable suspension is indicated for the treatment of metastatic breast cancer, metastatic adenocarcinoma of the pancreas, and locally advanced or metastatic non-small cell lung cancer. "Many patients living with difficult-to-treat cancers are faced with the unfortunate reality that the complex, life-saving treatments they need are too expensive or unavailable. At Meitheal, we're committed to closing this gap – we believe that today's launch is critical to ensuring that cancer patients get the medicines they need," said Tom Shea, Chief Executive Officer of Meitheal. "We're excited to bring this to market in the U.S. and provide patients and providers with a reliable supply of an effective cancer care treatment." The launch of paclitaxel increases Meitheal's portfolio of on-market generic injectables to 68 products, and builds on Meitheal's successful 12 product launches in 2024. In addition to paclitaxel, Meitheal is planning to launch 20 new products this year across its core therapeutic areas as it continues to identify gaps in the marketplace and evaluate opportunities to address the needs of both patients and providers. ABOUT PACLITAXELPaclitaxel protein-bound particles for injectable suspension (albumin-bound) is a type of chemotherapy, interfering with microtubules and causing cancerous cells to die. Paclitaxel is largely used for the treatment of metastatic breast cancer, and additional types of cancer. IMPORTANT SAFETY INFORMATIONINDICATIONSPaclitaxel protein-bound particles for injectable suspension (albumin-bound) is a microtubule inhibitor indicated for the treatment of: Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. SELECT IMPORTANT SAFETY INFORMATION WARNING: SEVERE MYELOSUPPRESSIONSee full prescribing information for complete boxed warning. Do not administer paclitaxel protein-bound particles for injectable suspension (albumin-bound) therapy to patients with baseline neutrophil counts of less than 1,500 cells/ for neutropenia, which may be severe and result in infection or frequent complete blood cell counts on all patients receiving paclitaxel protein-bound particles for injectable suspension (albumin-bound).CONTRAINDICATIONSNeutrophil counts of < 1,500 cells/mm3; and severe hypersensitivity reactions to paclitaxel protein-bound particles for injectable suspension (albumin-bound). WARNINGS AND PRECAUTIONSSensory neuropathy occurs frequently and may require dose reduction or treatment interruption. Sepsis occurred in patients with or without neutropenia who received paclitaxel protein-bound particles for injectable suspension (albumin-bound) in combination with gemcitabine; interrupt paclitaxel protein-bound particles for injectable suspension (albumin-bound) and gemcitabine until sepsis resolves, and if neutropenia, until neutrophils are at least 1,500 cells/mm3, then resume treatment at reduced dose levels. Pneumonitis occurred with the use of paclitaxel protein-bound particles for injectable suspension (albumin-bound) in combination with gemcitabine; permanently discontinue treatment with paclitaxel protein-bound particles for injectable suspension (albumin-bound) and gemcitabine. Severe hypersensitivity reactions with fatal outcome have been reported. Do not rechallenge with this drug. Exposure and toxicity of paclitaxel can be increased in patients with hepatic impairment, consider dose reduction and closely monitor patients with hepatic impairment. Paclitaxel protein-bound particles for injectable suspension (albumin-bound) contains albumin derived from human blood, which has a theoretical risk of viral transmission. Paclitaxel protein-bound particles for injectable suspension (albumin-bound) can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception. ADVERSE REACTIONSThe most common adverse reactions (≥ 20%) in metastatic breast cancer are alopecia, neutropenia, sensory neuropathy, abnormal ECG, fatigue/asthenia, myalgia/arthralgia, AST elevation, alkaline phosphatase elevation, anemia, nausea, infections, and diarrhea. DRUG INTERACTIONSUse caution when concomitantly administering paclitaxel protein-bound particles for injectable suspension (albumin-bound) with inhibitors or inducers of either CYP2C8 or CYP3A4. USE IN SPECIFIC POPULATIONS Lactation: Advise not to breastfeed. This is not the complete list of all the safety information for Paclitaxel protein-bound particles for injectable suspension (albumin-bound). Please click to see the full Prescribing Information for Paclitaxel protein-bound particles for injectable suspension (albumin-bound). ABOUT MEITHEAL PHARMACEUTICALS, in 2017 and based in Chicago, Meitheal is focused on the development and commercialization of generic injectable medications and, as of 2022, has expanded its focus to include fertility, biologic, and branded products. Meitheal currently markets over 60 U.S. FDA-approved products across numerous therapeutic areas including anti-infectives, oncolytics, intensive care, and fertility. As of April 2025, Meitheal, directly or through its partners, has 30 products in the research and development phase, 16 additional products planned for launch in 2025, and 23 products under review by the FDA. Meitheal's mission is to provide easy access to fairly priced products through robust manufacturing, consistent supply, and rapid response to our customers' needs. Ranked #2 in 2024 on Crain's Fast 50 in Chicago, and in the top 100 of Crain's Best Places to Work in Chicago from 2022 to 2024, Meitheal emulates the traditional Irish guiding principle we are named for—working together toward a common goal, for the greater good. Learn more about who we are and what we do at ABOUT HONG KONG KING-FRIEND INDUSTRIAL COMPANY (HKF)Hong Kong King-Friend Industrial Company is a wholly owned subsidiary of NKF, founded in 2010. ABOUT NANJING KING-FRIEND BIOPHARMACEUTICAL COMPANY (NKF)Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (NKF) is a China-based company principally engaged in the research and development, production and sales of Active Pharmaceutical Ingredients (API) and Finished Dosage Form (FDF). Established in 1986 as one of world leading manufacturers of heparin related APIs, NKF has grown into a fully integrated API and FDF manufacturer in multiple therapeutic areas including critical care and oncology. With three U.S. FDA approved manufacturing sites in China and more than 500 employees, including more than 100 dedicated research and development experts, NKF strives to meet patient needs globally with market presence in the U.S., China, EU and across the world. The Company is publicly listed on Shanghai Stock Exchange with a market capitalization over U.S. $3.0 billion. 1 Susan G. Komen Foundation. February 21, 2025. Metastatic Breast Cancer. 2 Abraxane® is a registered trademark of Celgene. View source version on Contacts MEDIA Meitheal Pharmaceuticals, Spilman, VP of Corporate Strategy773 899 5910info@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
29-05-2025
- Business
- Business Wire
Meitheal Pharmaceuticals Announces Launch of Generic Paclitaxel Formulation in the United States Through Exclusive Commercial Licensing Agreement
CHICAGO--(BUSINESS WIRE)--Meitheal Pharmaceuticals, Inc. ('Meitheal'), a fully integrated biopharmaceutical company based in Chicago and focused on the development and commercialization of generic injectables, fertility, biologic, and branded products, today announced it has launched, through an exclusive license and supply agreement with its parent company, Hong Kong King-Friend Industry Co., Ltd. ('HKF'), paclitaxel protein-bound particles for injectable suspension (albumin-bound), a generic form of Abraxane ®2, in the U.S. The 100mg/vial single-dose presentation of protein-bound paclitaxel for injectable suspension is indicated for the treatment of metastatic breast cancer, metastatic adenocarcinoma of the pancreas, and locally advanced or metastatic non-small cell lung cancer. 'Many patients living with difficult-to-treat cancers are faced with the unfortunate reality that the complex, life-saving treatments they need are too expensive or unavailable. At Meitheal, we're committed to closing this gap – we believe that today's launch is critical to ensuring that cancer patients get the medicines they need,' said Tom Shea, Chief Executive Officer of Meitheal. 'We're excited to bring this to market in the U.S. and provide patients and providers with a reliable supply of an effective cancer care treatment.' The launch of paclitaxel increases Meitheal's portfolio of on-market generic injectables to 68 products, and builds on Meitheal's successful 12 product launches in 2024. In addition to paclitaxel, Meitheal is planning to launch 20 new products this year across its core therapeutic areas as it continues to identify gaps in the marketplace and evaluate opportunities to address the needs of both patients and providers. ABOUT PACLITAXEL Paclitaxel protein-bound particles for injectable suspension (albumin-bound) is a type of chemotherapy, interfering with microtubules and causing cancerous cells to die. Paclitaxel is largely used for the treatment of metastatic breast cancer, and additional types of cancer. IMPORTANT SAFETY INFORMATION INDICATIONS Paclitaxel protein-bound particles for injectable suspension (albumin-bound) is a microtubule inhibitor indicated for the treatment of: Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. SELECT IMPORTANT SAFETY INFORMATION WARNING: SEVERE MYELOSUPPRESSION See full prescribing information for complete boxed warning. Do not administer paclitaxel protein-bound particles for injectable suspension (albumin-bound) therapy to patients with baseline neutrophil counts of less than 1,500 cells/mm3. Monitor for neutropenia, which may be severe and result in infection or sepsis. Perform frequent complete blood cell counts on all patients receiving paclitaxel protein-bound particles for injectable suspension (albumin-bound). CONTRAINDICATIONS Neutrophil counts of < 1,500 cells/mm3; and severe hypersensitivity reactions to paclitaxel protein-bound particles for injectable suspension (albumin-bound). WARNINGS AND PRECAUTIONS Sensory neuropathy occurs frequently and may require dose reduction or treatment interruption. Sepsis occurred in patients with or without neutropenia who received paclitaxel protein-bound particles for injectable suspension (albumin-bound) in combination with gemcitabine; interrupt paclitaxel protein-bound particles for injectable suspension (albumin-bound) and gemcitabine until sepsis resolves, and if neutropenia, until neutrophils are at least 1,500 cells/mm3, then resume treatment at reduced dose levels. Pneumonitis occurred with the use of paclitaxel protein-bound particles for injectable suspension (albumin-bound) in combination with gemcitabine; permanently discontinue treatment with paclitaxel protein-bound particles for injectable suspension (albumin-bound) and gemcitabine. Severe hypersensitivity reactions with fatal outcome have been reported. Do not rechallenge with this drug. Exposure and toxicity of paclitaxel can be increased in patients with hepatic impairment, consider dose reduction and closely monitor patients with hepatic impairment. Paclitaxel protein-bound particles for injectable suspension (albumin-bound) contains albumin derived from human blood, which has a theoretical risk of viral transmission. Paclitaxel protein-bound particles for injectable suspension (albumin-bound) can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception. ADVERSE REACTIONS The most common adverse reactions (≥ 20%) in metastatic breast cancer are alopecia, neutropenia, sensory neuropathy, abnormal ECG, fatigue/asthenia, myalgia/arthralgia, AST elevation, alkaline phosphatase elevation, anemia, nausea, infections, and diarrhea. DRUG INTERACTIONS Use caution when concomitantly administering paclitaxel protein-bound particles for injectable suspension (albumin-bound) with inhibitors or inducers of either CYP2C8 or CYP3A4. USE IN SPECIFIC POPULATIONS Lactation: Advise not to breastfeed. This is not the complete list of all the safety information for Paclitaxel protein-bound particles for injectable suspension (albumin-bound). Please click to see the full Prescribing Information for Paclitaxel protein-bound particles for injectable suspension (albumin-bound). ABOUT MEITHEAL PHARMACEUTICALS, INC. Founded in 2017 and based in Chicago, Meitheal is focused on the development and commercialization of generic injectable medications and, as of 2022, has expanded its focus to include fertility, biologic, and branded products. Meitheal currently markets over 60 U.S. FDA-approved products across numerous therapeutic areas including anti-infectives, oncolytics, intensive care, and fertility. As of April 2025, Meitheal, directly or through its partners, has 30 products in the research and development phase, 16 additional products planned for launch in 2025, and 23 products under review by the FDA. Meitheal's mission is to provide easy access to fairly priced products through robust manufacturing, consistent supply, and rapid response to our customers' needs. Ranked #2 in 2024 on Crain's Fast 50 in Chicago, and in the top 100 of Crain's Best Places to Work in Chicago from 2022 to 2024, Meitheal emulates the traditional Irish guiding principle we are named for—working together toward a common goal, for the greater good. Learn more about who we are and what we do at Hong Kong King-Friend Industrial Company is a wholly owned subsidiary of NKF, founded in 2010. ABOUT NANJING KING-FRIEND BIOPHARMACEUTICAL COMPANY (NKF) Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (NKF) is a China-based company principally engaged in the research and development, production and sales of Active Pharmaceutical Ingredients (API) and Finished Dosage Form (FDF). Established in 1986 as one of world leading manufacturers of heparin related APIs, NKF has grown into a fully integrated API and FDF manufacturer in multiple therapeutic areas including critical care and oncology. With three U.S. FDA approved manufacturing sites in China and more than 500 employees, including more than 100 dedicated research and development experts, NKF strives to meet patient needs globally with market presence in the U.S., China, EU and across the world. The Company is publicly listed on Shanghai Stock Exchange with a market capitalization over U.S. $3.0 billion. 1 Susan G. Komen Foundation. February 21, 2025. Metastatic Breast Cancer. 2 Abraxane ® is a registered trademark of Celgene.
